OTCMKTS:DSRLF DiaSorin (DSRLF) Stock Forecast, Price & News $91.00 -0.60 (-0.66%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$91.00▼$91.0050-Day Range$91.00▼$97.9852-Week Range$91.00▼$147.15Volume35 shsAverage Volume13 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$201.25 ProfileProfileAnalyst RatingsChartCompetitorsHeadlinesShort InterestProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest About DiaSorin (OTCMKTS:DSRLF) StockDiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.Read More DSRLF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSRLF Stock News HeadlinesJuly 27, 2023 | msn.comDiaSorin S.p.A. reports 1H resultsMay 9, 2023 | msn.comDiaSorin confirms 2023 guidance after Q1 resultsSeptember 23, 2023 | Stansberry Research (Ad)U.S. "Shadow Banks" About to Blow up again?Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.April 6, 2023 | barrons.comDiaSorin S.p.A.March 29, 2023 | seekingalpha.comDiaSorin S.p.A. (DSRLF) Q4 2022 Earnings Call TranscriptMarch 4, 2023 | seekingalpha.comDiaSorin: Overvalued Italian Healthcare CompanyFebruary 15, 2023 | wsj.comCytek(R) Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorinFebruary 13, 2023 | finance.yahoo.comCytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorinSeptember 23, 2023 | Stansberry Research (Ad)U.S. "Shadow Banks" About to Blow up again?Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.October 31, 2022 | reuters.comDIAS.MI - DiaSorin SpA | Stock Price & Latest News | ReutersAugust 8, 2022 | seekingalpha.comDiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2022 Results - Earnings Call TranscriptOctober 23, 2021 | finance.yahoo.comSouthwest Airlines Company (LUV) stock forecast and price targetAugust 2, 2021 | seekingalpha.comDiaSorin S.p.A. 2021 Q2 - Results - Earnings Call PresentationApril 21, 2021 | businesswire.comQIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early ...April 13, 2021 | finance.yahoo.comLuminex (LMNX) to Get Acquired by DiaSorin for Around $1.8BApril 12, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Luminex Corporation BuyoutApril 12, 2021 | markets.businessinsider.comDiaSorin To Buy Luminex For $1.8 BlnApril 12, 2021 | finance.yahoo.comShareholder Alert: Ademi LLP investigates whether Luminex Corporation has obtained a Fair Price in its transaction with DiaSorinApril 12, 2021 | investing.comLuminex Jumps on $1.8 Billion Deal from Italy’s DiaSorinApril 12, 2021 | msn.comLuminex Jumps on $1.8 Billion Pact to Be Bought by DiaSorinApril 12, 2021 | finance.yahoo.comUPDATE 1-Shares in Italy's DiaSorin jump after $1.8 bln Luminex acquisitionApril 11, 2021 | bloomberg.comDiaSorin to Buy Covid-19 Test Maker Luminex for $1.8 BillionMarch 13, 2021 | seekingalpha.comDiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2020 Results - Earnings Call TranscriptMarch 11, 2021 | seekingalpha.comDiaSorin S.p.A. reports FY resultsFebruary 25, 2021 | msn.comDiaSorin Weighs Diagnostics Deal for LuminexNovember 13, 2020 | seekingalpha.comDiaSorin S.p.A. 2020 Q3 - Results - Earnings Call PresentationNovember 11, 2020 | marketwatch.comDisplay Dielectric Materials Market Trends to Expand Significantly by 2027 | DiaSorin S.p.A, Becton, Dickinson and Company, SA ScientificSee More Headlines Receive DSRLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaSorin and its competitors with MarketBeat's FREE daily newsletter. Email Address DSRLF Company Calendar Today9/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Private households Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:DSRLF CUSIPN/A CIKN/A Webwww.diasoringroup.com Phone391614871FaxN/AEmployees3,358Year FoundedN/APrice Target and Rating Average Stock Price Forecast$201.25 High Stock Price Forecast$201.25 Low Stock Price Forecast$201.25 Forecasted Upside/Downside+119.7%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.46 billion Price / Sales3.42 Cash Flow$9.80 per share Price / Cash Flow9.35 Book Value$29.58 per share Price / Book3.10Miscellaneous Outstanding Shares54,710,000Free FloatN/AMarket Cap$5.01 billion OptionableNot Optionable Beta0.39 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Carlo Rosa (Age 57)CEO, GM & Exec. Director Comp: $1.88MDr. Chen Menachem Even (Age 60)Chief Commercial Officer, Sr. Corp. VP of Commercial Operations & Exec. Director Comp: $919.27kMr. Piergiorgio Pedron (Age 52)Sr. Corp. VP, CFO & Corp. Accounting Documents Officer Mr. Fabrizio Piercarlo BonelliCorp. VP & Chief Technology OfficerDr. Riccardo FavaCorp. VP of Communication & Investor RelationsMr. Ulisse SpadaCorp. VP, Head of the Legal Department, Sec. & Gen. CounselMr. Stefano Ronchi (Age 63)Sr. Corp. VP of HR Mr. Ugo Gay (Age 58)Chief Exec. Officer of DiaSorin Italia S.p.A. Mr. Angelo Rago (Age 60)Pres of Luminex Corp. More ExecutivesKey CompetitorsRespiriOTCMKTS:KMLXFSemperit AktiengesellschaftOTCMKTS:SEIGYSunny Optical Technology (Group)OTCMKTS:SNPTF1933 IndustriesOTCMKTS:TGIFF3SBioOTCMKTS:TRSBFView All Competitors DSRLF Stock - Frequently Asked Questions Should I buy or sell DiaSorin stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DiaSorin in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" DSRLF shares. View DSRLF analyst ratings or view top-rated stocks. What is DiaSorin's stock price forecast for 2023? 6 brokerages have issued twelve-month target prices for DiaSorin's stock. Their DSRLF share price forecasts range from $201.25 to $201.25. On average, they anticipate the company's stock price to reach $201.25 in the next year. This suggests a possible upside of 119.7% from the stock's current price. View analysts price targets for DSRLF or view top-rated stocks among Wall Street analysts. How have DSRLF shares performed in 2023? DiaSorin's stock was trading at $147.15 at the beginning of 2023. Since then, DSRLF stock has decreased by 37.8% and is now trading at $91.5995. View the best growth stocks for 2023 here. What is DiaSorin's stock symbol? DiaSorin trades on the OTCMKTS under the ticker symbol "DSRLF." How do I buy shares of DiaSorin? Shares of DSRLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DiaSorin's stock price today? One share of DSRLF stock can currently be purchased for approximately $91.60. How much money does DiaSorin make? DiaSorin (OTCMKTS:DSRLF) has a market capitalization of $5.01 billion and generates $1.46 billion in revenue each year. How many employees does DiaSorin have? The company employs 3,358 workers across the globe. How can I contact DiaSorin? DiaSorin's mailing address is Via Crescentino, Saluggia L6, 13040. The official website for the company is www.diasoringroup.com. The company can be reached via phone at 391614871 or via email at ines.diterlizzi@diasorin.it. This page (OTCMKTS:DSRLF) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaSorin S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.